EMA Recommends Approval of Spikevax for Children Aged 6 to 11

News
Article

EMA has recommended approval of Spikevax for children aged 6 to 11.

EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting approval of Moderna’s COVID-19 vaccine Spikevax to include use in children aged 6–11. Spikevax is already approved for use in adults and adolescents aged 12 and up.

The CHMP has concluded that the efficacy and safety of Spikevax in children aged 6–11 are also similar to those in adults, and that the benefits of using the vaccine on this age group outweigh the risks. The CHMP will send its recommendation to the European Commission (EC), which will issue a final decision.

The dose of Spikevax in children aged 6–11 will be lower than that used in people aged 12 and above. The most common side effects of the vaccine are similar between children aged 6–11 and adults, some of which include pain, redness and swelling at the injection site, tiredness, headache, and chills. These side effects are usually mild or moderate and improve within a few days.

Ongoing and additional studies are being conducted by the company as well as European authorities to further monitor the safety and efficacy of the vaccine in both children and adults.

Source: EMA

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes